Business

Merck settles suits on cholesterol drugs for $688m

The suits against Merck concerned Zetia and Vytorin pills.

Jeff Zelevansky/Reuters

The suits against Merck concerned Zetia and Vytorin pills.

TRENTON, N.J.— Merck & Co. has agreed to pay $688 million to settle two long-running lawsuits brought by investors who alleged that the drugmaker delayed releasing bad news on its blockbuster cholesterol drugs to prevent a drop in sales.

Merck, the world’s third biggest drugmaker by revenue, said Thursday that it agreed to the settlement because it is in the best interest of the company and current shareholders. It is taking a charge of nearly a half-billion dollars against 2012 earnings.

Advertisement

The delay in releasing results of a study that was meant to bolster sales of pricey cholesterol pills Zetia and Vytorin triggered criticism by analysts, investors, some scientists, and the media — and ultimately an investigation by Congress.

The maker of Januvia Type 2 diabetes pills and the Gardasil vaccine against sexually transmitted cancers admitted no wrongdoing. The deal must be approved by a federal judge.

Get Talking Points in your inbox:
An afternoon recap of the day’s most important business news, delivered weekdays.
Thank you for signing up! Sign up for more newsletters here

‘‘The settlement gets a cloud out of the sky for Merck,’’ said Erik Gordon, an analyst and professor at University of Michigan’s Ross School of Business.

The settlement is among the top 25 securities class action settlements ever, according to Bernstein Litowitz Berger & Grossmann LLP, co-lead counsel in the litigation brought by a number of large pension funds.

Merck, which is based in Whitehouse Station, said in a statement that it is taking a charge of $493 million. The company also restated previously reported financial results, reducing its 2012 fourth-quarter results to 30 cents per share from 46 cents per share, and its 2012 results to $2 per share from $2.16 per share.

Advertisement

Merck shares rose 4 cents to close at $41.19. They have traded in a 52-week range of $36.91 last March to $48 in mid-October.

Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.
You're reading  1 of 5 free articles.
Get UNLIMITED access for only 99¢ per week Subscribe Now >
You're reading1 of 5 free articles.Keep scrolling to see more articles recomended for you Subscribe now
We hope you've enjoyed your 5 free articles.
Continue reading by subscribing to Globe.com for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com